Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy-Reference-Cited by-同舟云学术

Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Published:2022-07 Issue:4 Volume:8 Page:958-967
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Oudard Stéphane^ORCID,Hadaschik Boris,Saad Fred,Cella David,Basch Ethan,Graff Julie N.,Uemura Hiroji,Dibaj Shiva,Li Susan,Brookman-May Sabine D.,De Porre Peter,Bevans Katherine B.,Trudeau Jeremiah J.,Small Eric J.,Smith Matthew R.

Publisher

Elsevier BV

Reference17 articles.

1. ARN-509: a novel antiandrogen for prostate cancer treatment;Clegg;Cancer Res,2012

2. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018

3. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer;Small;Ann Oncol,2019

4. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial;Saad;Lancet Oncol,2018

5. Erleada (apalutamide) prescribing information;Janssen,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. French AFU Cancer Committee Guidelines – Update 2024–2026: Prostate cancer – Management of metastatic disease and castration resistance;The French Journal of Urology;2024-11

2. Recommandations françaises du Comité de cancérologie de l’AFU – Actualisation 2024–2026 : cancer de la prostate – traitement de la récidive et de la maladie métastatique;Progrès en Urologie - FMC;2024-11

3. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer;European Urology Oncology;2024-08

4. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy;BJU International;2024-06-28

5. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR);The Oncologist;2024-03-07